دورية أكاديمية
أعرض في EDS

Extracellular vesicles are a late marker of inflammation, hypercoagulability and COVID-19 severity.

التفاصيل البيبلوغرافية
العنوان: Extracellular vesicles are a late marker of inflammation, hypercoagulability and COVID-19 severity.
المؤلفون: Barion BG; Universidade de Sao Paulo (USP), Sao Paulo, Brazil., Rocha TRFD; Hospital das Clínicas da Faculdade de Medicina da Universidade de São (HCFMUSP), Sao Paulo, Brazil., Ho YL; Hospital das Clínicas da Faculdade de Medicina da Universidade de São (HCFMUSP), Sao Paulo, Brazil., Mazetto Fonseca BM; Hematology and Hemotherapy Center of the University of Campinas (UNICAMP), Campinas, Brazil., Okazaki E; Hospital das Clínicas da Faculdade de Medicina da Universidade de São (HCFMUSP), Sao Paulo, Brazil., Rothschild C; Hospital das Clínicas da Faculdade de Medicina da Universidade de São (HCFMUSP), Sao Paulo, Brazil., Stefanello B; Hospital das Clínicas da Faculdade de Medicina da Universidade de São (HCFMUSP), Sao Paulo, Brazil., Rocha VG; Hospital das Clínicas da Faculdade de Medicina da Universidade de São (HCFMUSP), Sao Paulo, Brazil., Villaça PR; Hospital das Clínicas da Faculdade de Medicina da Universidade de São (HCFMUSP), Sao Paulo, Brazil., Orsi FA; Hospital das Clínicas da Faculdade de Medicina da Universidade de São (HCFMUSP), Sao Paulo, Brazil; Department of Pathology, School of Medical Sciences, Universidade de Campinas (UNICAMP), Campinas, Brazil. Electronic address: ferorsi@unicamp.br.
المصدر: Hematology, transfusion and cell therapy [Hematol Transfus Cell Ther] 2024 Apr-Jun; Vol. 46 (2), pp. 176-185. Date of Electronic Publication: 2024 Feb 01.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Editora Ltda Country of Publication: Brazil NLM ID: 101725732 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2531-1387 (Electronic) Linking ISSN: 25311379 NLM ISO Abbreviation: Hematol Transfus Cell Ther Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Rio de Janeiro, Brazil] : Elsevier Editora Ltda, [2018]-
مستخلص: Exacerbated inflammation and coagulation are a hallmark of COVID-19 severity. Extracellular vesicles (EVs) are intercellular transmitters involved in inflammatory conditions, which are capable of triggering prothrombotic mechanisms. Since the release of EVs is potentially associated with COVID-19-induced coagulopathy, the aim of this study was to evaluate changes in inflammation- and hypercoagulability-related EVs during the first month after symptom onset and to determine whether they are associated with disease severity. Blood samples of patients with mild or severe forms of the disease were collected on three occasions: in the second, third and fourth weeks after symptom onset for the quantification by flow cytometry of CD41A (platelet glycoprotein IIb/IIIa), CD162 (PSGL-1), CD31 (PECAM-1) and CD142 cells (tissue factor). Analysis of variance (ANOVA) with repeated measures, Kruskal-Wallis and correlation tests were used. Eighty-five patients were enrolled, 71% of whom had mild disease. Seventeen uninfected individuals served as controls. Compared to controls, both mild and severe COVID-19 were associated with higher EV-CD31 + , EV-CD41 + and EV-CD142 + levels. All EV levels were higher in severe than in mild COVID-19 only after the third week from symptom onset, as opposed to C-reactive protein and D-dimer levels, which were higher in severe than in mild COVID-19 earlier during disease progression. EV levels were also associated with C-reactive protein and D-dimer levels only after the third week of symptoms. In conclusion, EVs expressing CD41A, CD31, TF, and CD162 appear as late markers of COVID-19 severity. This finding may contribute to the understanding of the pathogenesis of acute and possibly long COVID-19.
Competing Interests: Conflicts of interest The authors declare they have no conflicts of interest.
(Copyright © 2024 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier España, S.L.U. All rights reserved.)
References: J Thromb Haemost. 2018 Jun;16(6):1236-1245. (PMID: 29575716)
Ann Med. 2019 May - Jun;51(3-4):193-223. (PMID: 31007084)
Nat Med. 2022 May;28(5):879-882. (PMID: 35383311)
Lancet Infect Dis. 2022 Apr;22(4):e102-e107. (PMID: 34951953)
Eur Respir J. 2021 Sep 9;58(3):. (PMID: 33958433)
Front Cell Dev Biol. 2022 Jan 17;9:770463. (PMID: 35111751)
BMJ Open. 2021 Apr 7;11(4):e047121. (PMID: 33827848)
Int J Mol Sci. 2019 Jun 11;20(11):. (PMID: 31212641)
Ann Intern Med. 2021 Jan;174(1):33-41. (PMID: 32960645)
Theranostics. 2021 Jul 6;11(16):8076-8091. (PMID: 34335981)
J Thromb Haemost. 2018 May 31;:. (PMID: 29851269)
Arterioscler Thromb Vasc Biol. 2021 Feb;41(2):878-882. (PMID: 33267656)
Lancet Respir Med. 2021 Apr;9(4):349-359. (PMID: 33444539)
J Extracell Vesicles. 2021 Jul;10(9):e12117. (PMID: 34262673)
Arch Cardiovasc Dis. 2023 Apr;116(4):183-191. (PMID: 36858909)
Blood Adv. 2020 Jul 14;4(13):3011-3023. (PMID: 32614966)
Nat Commun. 2020 Oct 6;11(1):5033. (PMID: 33024092)
JAMA Intern Med. 2020 Aug 1;180(8):1081-1089. (PMID: 32396163)
Biochemistry (Mosc). 2016 Apr;81(4):382-391. (PMID: 27293095)
Front Immunol. 2018 Dec 13;9:2723. (PMID: 30619239)
Blood Adv. 2022 Jun 14;6(11):3367-3377. (PMID: 35235941)
Circ Res. 2020 Sep 17;:. (PMID: 32938299)
Lancet Respir Med. 2021 Feb;9(2):129. (PMID: 33453162)
Blood Adv. 2021 Feb 9;5(3):628-634. (PMID: 33560376)
Infect Drug Resist. 2022 Apr 29;15:2359-2368. (PMID: 35517897)
Nat Commun. 2021 Dec 9;12(1):7135. (PMID: 34887400)
Nat Commun. 2022 Apr 5;13(1):1812. (PMID: 35383197)
Vox Sang. 2011 Feb;100(2):187-95. (PMID: 20738837)
Cell Death Dis. 2021 Oct 1;12(10):894. (PMID: 34599143)
فهرسة مساهمة: Keywords: Biomarkers; COVID-19; Extracellular vesicles; Hypercoagulability; Inflammation
تواريخ الأحداث: Date Created: 20240210 Latest Revision: 20240607
رمز التحديث: 20240607
مُعرف محوري في PubMed: PMC11150502
DOI: 10.1016/j.htct.2023.12.003
PMID: 38341321
قاعدة البيانات: MEDLINE
الوصف
تدمد:2531-1387
DOI:10.1016/j.htct.2023.12.003